Iris Parent Holding CORP 8-K filings

Liminatus Pharma, Inc. announced strong shareholder approval at its 2026 Annual Meeting for director elections, auditor ratification, and a reverse stock split authorization necessary for Nasdaq compliance.

Liminatus Pharma, Inc. reports stockholder equity exceeding $2.5 million post-merger, awaiting Nasdaq's compliance determination while acknowledging ongoing monitoring.

Liminatus Pharma received a notice from Nasdaq indicating it has not regained compliance with the minimum bid price rule and is not eligible for a second extension, with a decision on continued listing pending.

Liminatus Pharma, Inc. has finalized its acquisition of InnocsAI LLC, amending the merger agreement to include convertible preferred stock as part of the consideration.

Liminatus Pharma announced a warrant exercise inducement offer, resulting in $1.9 million in gross proceeds and the issuance of new warrants.

Liminatus Pharma received a delisting notice from Nasdaq for failing to meet market value requirements, but has requested an appeal.

Liminatus Pharma, Inc. has entered into a definitive merger agreement to acquire InnocsAI LLC in an all-stock transaction valued at approximately $320 million.

Liminatus Pharma, Inc. amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of voting power, effective February 27, 2026.

Liminatus Pharma, Inc. announced a settlement agreement with Clear Street LLC, resolving two lawsuits by issuing 4 million shares in exchange for warrant cancellation and dismissing a $7.5 million default judgment.

Liminatus Pharma, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1 bid price rule, initiating a 180-day compliance period.

Liminatus Pharma, Inc. received notices from Nasdaq for failing to meet minimum market value requirements, initiating a 180-day compliance period.

Liminatus Pharma, Inc. announced it received a Nasdaq non-compliance notice due to a delay in filing its quarterly report, risking its stock listing.

Liminatus Pharma highlights its IBA101 CD47 inhibitor as a strategic solution for pharmaceutical companies facing the impending patent cliff of blockbuster PD-1/L1 immuno-oncology drugs.

Liminatus Pharma, Inc. entered into a settlement agreement with Alta Partners, LLC, issuing 350,000 shares of common stock in exchange for the cancellation of 1,000,000 warrants.

Liminatus Pharma, Inc. announced the expansion of its board of directors to six members and the immediate appointment of Philip Lemons and Richard Baek, bringing extensive expertise in clinical research and financial oversight.

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding with Samda Biolab Co., Ltd. and INNOCS AI to form a research and development consortium focused on a novel, high-performance blood-based diagnostic kit for early pancreatic cancer detection.

Liminatus Pharma announced significant progress for its next-generation CD47 inhibitor, IBA101, completing pivotal preclinical studies and setting a timeline for human trials in the U.S. and Korea.

Liminatus Pharma, recently listed on Nasdaq, has detailed its lead asset IBA101, a next-generation CD47 immune checkpoint inhibitor designed to overcome previous safety limitations and achieve synergistic anti-tumor effects, with plans for Phase 1 trials and significant licensing deals.

Liminatus Pharma, a pre-clinical stage biopharmaceutical company, announced it has regained compliance with Nasdaq listing requirements following the timely filing of its Quarterly Report on Form 10-Q.

Liminatus Pharma, Inc. has completed its business combination and commenced trading on Nasdaq, but the pre-clinical stage biopharmaceutical company faces substantial doubt about its ability to continue as a going concern due to significant accumulated losses and ongoing funding needs.

Liminatus Pharma finalizes its merger with Iris Acquisition Corp, marking its debut on the Nasdaq stock market under the ticker symbols LIMN and LIMNW.

Liminatus Pharma, a pre-clinical stage biopharmaceutical company, finalized its business combination with Iris Acquisition Corp and will commence trading on the Nasdaq under the ticker symbols LIMN and LIMNW on May 1, 2025.